CYP 3A

CYP 3A

a cytochrome P450 isoform found in the gastrointestinal tract as well as hepatic and other cells; substrates include benzodiazepines, calcium channel blockers, antihistamines, steroid hormones, and protease inhibitors. Inhibited by antidepressants, azole antifungals, cimetidine, grapefruit juice, and erythromycin. Induced by phenobarbital, phenytoin, rifampin, and carbamazepine.

CYP 3A

Abbreviation for a cytochrome P450 isoform found in the gastrointestinal tract as well as hepatic and other cells; substrates include benzodiazepines, calcium channel blockers, antihistamines, steroid hormones, and protease inhibitors. Inhibited by antidepressants, azole antifungals, cimetidine, and erythromycin. Induced by phenobarbital, phenytoin, rifampin, and carbamazepine.
Mentioned in ?
References in periodicals archive ?
Studying the Interplay Between CYP 3A and Drug Transporters Using Knockout Mice by Robert van Waterschoot, Laboratory Head DMPK Abbott Laboratories|
MULTAQ should not be coadministered with strong CYP 3A inhibitors, such as ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, ritonavir, or drugs or herbal products that prolong the QT interval and might increase the risk of Torsade de Pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain macrolide antibiotics, and Class I and III antiarrhythmics.
Treatment with Class I or III antiarrhythmics or drugs that are strong inhibitors of CYP 3A must be stopped before starting MULTAQ (see Contraindications).
The members of CYP 3A are mainly found in the liver, intestine and peripheral blood cells (Shimada et al.
MULTAQ should not be coadministered with strong CYP 3A inhibitors or medicinal products that prolong the QT interval.
SAMSCA is contraindicated in the following conditions: Urgent need to raise serum sodium acutely, inability of the patient to sense or appropriately respond to thirst, hypovolemic hyponatremia, concomitant use of strong CYP 3A inhibitors, anuric patients
Inhibition of CYP 3A activity by administration of ketoconazole 400 mg daily does not affect rofecoxib disposition.